Global partnership to make available 120 million
A full access package includes WHO policy guidance on the use of antigen based rapid diagnostic tests manufacturer volume guarantees for low and middle income countries catalytic funding to assist governments to deploy the tests and an initial US$50 million procurement fundSeveral rapid point of care antigen tests are being assessed by WHO for Emergency Use Listing EUL Agreements